New indications for BMS' Breyanzi approved in Europe

The European Commission (EC) has approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for a number of new lymphoma indications.

Developed by US pharma major Bristol Myers Squibb (NYSE: BMY), Breyanzi is now cleared for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

In DLBCL, the most common form of non-Hodgkin lymphoma, up to 40% of patients will become refractory to or will relapse following initial therapy, therefore leaving a continued unmet need for second-line treatment options with curative potential.